Zuvog Trio 2 Tablet SR

Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, promoting better glucose uptake by tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, attenuating postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, maintaining stable plasma concentrations and improving patient compliance by reducing dosing frequency.

Zuvog Trio 2 is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy. It should be used cautiously in patients with renal or hepatic impairment, and contraindicated in those with diabetic ketoacidosis, severe infections, or hypersensitivity to any component. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia and gastrointestinal disturbances is essential.

This combination therapy offers a comprehensive approach to glycemic management by targeting multiple pathophysiological defects in type 2 diabetes.